Royal Bank Of Canada Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective decreased by equities researchers at Royal Bank Of Canada from $22.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target points to a potential downside of 2.96% from the company’s current price.

A number of other equities research analysts have also commented on the company. William Blair reiterated an “outperform” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 15th. Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 29th. HC Wainwright upped their price target on shares of Apellis Pharmaceuticals from $45.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Bank of America raised Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Wednesday, January 21st. Twelve investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $32.61.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $21.64 on Wednesday. The firm has a market capitalization of $2.77 billion, a PE ratio of 166.47 and a beta of 0.26. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 3.10. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $30.48. The company’s fifty day moving average price is $23.07 and its 200-day moving average price is $23.81.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. The company had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The firm’s revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.29) EPS. On average, equities research analysts predict that Apellis Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, insider Pascal Deschatelets sold 5,928 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $129,052.56. Following the completion of the transaction, the insider owned 1,151,382 shares in the company, valued at $25,065,586.14. The trade was a 0.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David O. Watson sold 7,832 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $170,502.64. Following the transaction, the general counsel owned 88,531 shares in the company, valued at $1,927,319.87. This represents a 8.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 120,537 shares of company stock valued at $2,608,532. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jones Financial Companies Lllp grew its stake in Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after acquiring an additional 1,373 shares during the period. Osaic Holdings Inc. lifted its holdings in Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares in the last quarter. Allworth Financial LP lifted its holdings in Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at about $64,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long‑range outlook (FY2030 EPS to $1.97), reiterated a “Buy” and lifted its price target to $48 — a strongly bullish signal that likely supported buying interest this session. HC Wainwright raises target to $48
• Neutral Sentiment: Citigroup trimmed its target from $45 to $44 but kept a “Buy” rating — a modestly cautious move that is unlikely to materially change conviction among bullish investors. Citigroup price target update
• Neutral Sentiment: Earnings/transcript sources for the Feb. 24 Q4 call are circulating (full transcript available) — the call contains detail investors will parse for guidance and product trends; headlines are mixed across outlets. Earnings call transcript (Yahoo) Earnings call transcript (InsiderMonkey)
• Neutral Sentiment: Short‑interest data released shows “0 shares” and NaN changes — this is almost certainly a reporting or processing error and should not be treated as a genuine change in borrow/short pressure.
• Negative Sentiment: Royal Bank of Canada cut its target to $21 and moved to “Sector Perform,” which signals lower near‑term expectations and adds selling pressure for more cautious holders. RBC target cut Coverage note
• Negative Sentiment: Wedbush lowered its target to $18 and moved to “Neutral,” another sign of reduced analyst conviction that could weigh on the stock if follow‑through selling occurs. Wedbush target cut Coverage note
• Negative Sentiment: Zacks flagged a wider‑than‑expected Q4 loss and an 8% slip in Syfovre sales (though total revenue beat estimates and Empaveli grew on a new indication) — mixed results that may keep some investors cautious until product trends clarify. Zacks earnings summary

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.